Navigation Links
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Date:4/25/2012

HAYWARD, Calif., April 25, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the completion of dosing in the Company's Phase 2b PEARL-SC study. PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of monthly and weekly subcutaneous administration of blisibimod in systemic lupus erythematosus (SLE) patients.

The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in an SLE responder index  (SRI)-- a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI* improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.

In addition to the primary endpoint analysis, PEARL-SC will provide a series of key secondary subgroup and endpoint analyses which will help guide the design of phase 3 registration studies and further differentiate blisibimod from currently available therapies.  These prospective secondary and exploratory analyses include:

  • Larger improvement in disease activity, as measured by SELENA/SLEDAI reductions of 5, 6, 7 and 8;
  • The percentage of patients achieving the primary endpoint and requiring no increase in steroid dose from baseline;
  • Percentage of patients able to reduce steroid dose and percentage of patients requiring no increase in steroid dose;
  • Time to first SLE flare and first severe SLE flare;
  • Disease activity improvement in lupus patients
    '/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ... of the "Global Advanced Wound Care and ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... advanced wound care and closure market (types, applications, ...
(Date:8/20/2014)... ARBOR, Mich. and PHOENIX ... non-profit corporation established to bring cutting-edge next-generation sequencing ... to cancer patients, today announced a collaboration with ... capabilities to characterize patient tissue samples from clinical ... sensitive or resistant to TESARO,s TSR-011.  This may lead ...
(Date:8/20/2014)... LAKE WORTH, Fla. , Aug. 20, 2014  Glades ... Florida , is proud to announce its expansion into ... , which will feature an 8,000-square-foot office space and ... is currently accepting applications for 100 open positions for the ... located at 4560 Lantana Road will serve as the chain,s ...
Breaking Medicine Technology:Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
... in Peer-Review Journal,Respiratory Medicine, SAN JOSE, Calif., ... Pulmonary Fibrosis (CPF) today announced a summary ... of the,largest databases of information on patients ... United States, was,published in Respiratory Medicine. The ...
... OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed,Inc. announced ... on,novel, synthetic dermal fillers is being presented at ... March,22-24, 2007., In 2006, FzioMed launched Laresse Dermal ... the,company's patented polymer science. Laresse represents a completely,new ...
Cached Medicine Technology:Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients 2Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients 3Laresse Dermal Filler Research Presented at Anti-Aging World,Congress 2
(Date:8/20/2014)... 20, 2014 Botanica Day ... facial. Utilizing the new and popular stem cell ... fine lines and wrinkles and naturally repairs the ... highlighting the new service by offering clients a ... stem cell facial. , Pevonia® continues to be ...
(Date:8/20/2014)... -- Leaving the car at home and getting to work ... health, a new study indicates. Researchers looked at thousands ... percent of men and 72 percent of women drove to ... used public transit, and 14 percent of men and 17 ... to work weighed more and had higher levels of body ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... 20, 2014 Fresh from the cradle of ... sprung from the starting blocks. , Urbini, a new collection ... the Urbini Avi jogger to its lineup. , ... with a look inspired by the latest racing styles and ... , This versatile jogger offers a swift, smooth ride on ...
(Date:8/20/2014)... August 20, 2014 The National ... five-year, $1.24 million Science Education Partnership Award (SEPA) ... support NAHN’s collaborative project with the Hispanic Communications ... Careers. , This collaborative NIH R25 program has ... and linguistic diversity among health professionals by recruiting ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... Irvine scientists will receive grants totaling $9.35 million to ... disease and traumatic brain injury. The grants from ... Oct. 21, to Dr. Henry Klassen, Leslie M. Thompson, ... the Sue and Bill Gross Stem Cell Research Center ...
... interdisciplinary approach to drug abuse and addiction research, The ... has been renewed as a "Center of Excellence" by ... National Institutes of Health. The designation comes with ... to further studies led by researchers and clinicians in ...
... University of California, San Diego School of Medicine indicates that ... plans that include parents and child, while at the same ... , The results were published today in the advanced online ... Boutelle, PhD, associate professor of pediatrics and psychiatry at UC ...
... (HealthDay News) -- A new study suggests that in women ... tissue in addition to a cancerous breast tumor is enough ... about how much of a "free margin" around a tumor ... the November issue of IJCP, the International Journal of ...
... A new research study conducted by Boston University ... significantly improve biennial mammography screening rates among inner city ... Journal of General Internal Medicine , indicate the importance ... patient populations. Breast cancer is the second ...
... , THURSDAY, Oct. 21 (HealthDay News) -- Over the ... in the United States will be 10 times greater ... that could affect cancer patients, access to treatment, according ... the number of patients requiring radiation therapy will increase ...
Cached Medicine News:Health News:UCI stem cell researchers to receive $9.35 million in state funding 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 3Health News:UTHealth receives $11 million NIDA grant 2Health News:Parent-only treatment may be equally effective for children who are obese 2Health News:New Finding Suggests Safe Surgical Margins When Removing Breast Cancers 2Health News:BUSM study shows patient navigations improve mammography rates in minority women 2Health News:Demand for Radiation Therapy Predicted to Exceed Supply 2
The focus of HandEchart Professional is to offer a practical and basic electronic patient record keeping system that anyone can learn in minutes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
A handy quick-reference tool for busy residents and clinicians with key facts and points essential for day-to-day patient care....
Medicine Products: